

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXJ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	6	JUN 29	EFFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	9	JUL 27	CA/CAPLUS enhanced with new citing references
NEWS	10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS	11	JUL 21	USGENE adds bibliographic and sequence information
NEWS	12	JUL 28	EFFULL adds first-page images and applicant-cited references
NEWS	13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS	14	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	15	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	16	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	17	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	18	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	19	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS EXPRESS	MAY 26 09		CURRENT WINDOWS VERSION IS V8.4, AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:32:56 ON 17 SEP 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.44

0.44

FILE 'REGISTRY' ENTERED AT 14:33:53 ON 17 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 SEP 2009 HIGHEST RN 1185221-67-3

DICTIONARY FILE UPDATES: 16 SEP 2009 HIGHEST RN 1185221-67-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s piketoprofen

L1 2 PIKETOPROFEN

=> d l1 1-2

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN

RN 60576-13-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)

OTHER NAMES:


CN Piketoprofen

MF C22 H20 N2 O2

CI COM

LC STN Files: ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSPATENTS, IMSPRODUCT, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL (*File contains numerically searchable property data)


Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

35 REFERENCES IN FILE CA (1907 TO DATE)
35 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
RN 59512-37-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)-,
hydrochloride (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)-,
monohydrochloride (9CI)
OTHER NAMES:
CN Piktoprofen hydrochloride
MF C22 H20 N2 O2 . Cl H
LC STN Files: BEILSTEIN*, CA, CAPLUS, IMSPATENTS, MRCK*, PS, TOXCENTER,
USPATFULL
(*File contains numerically searchable property data)
CRN (60576-13-8)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
9.93	10.37

FILE 'CAPLUS' ENTERED AT 14:34:30 ON 17 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Sep 2009 VOL 151 ISS 12
FILE LAST UPDATED: 16 Sep 2009 (20090916/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s l1

L2 37 L1

=> s l2 and skin

308899 SKIN

L3 11 L2 AND SKIN

=> s l2 and (skin or inflammation or derm6)

6) IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s l2 and (skin or inflammation or dermatitis)

308899 SKIN

218807 INFLAMMATION

23593 DERMATITIS

L4 21 L2 AND (SKIN OR INFLAMMATION OR DERMATITIS)

=> d l4 1-21 ibib abs hitstr

L4 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2008:1534344 CAPLUS

DOCUMENT NUMBER: 150:83825

TITLE: Topical compositions containing NSAIDs and alcohols as solvents

INVENTOR(S): Spann-Wade, Monique; Fedde, Kenton N.

PATENT ASSIGNEE(S): ISW Group, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 50pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080317684	A1	20081225	US 2007-842201	20070821
AU 2007293460	A1	20080313	AU 2007-293460	20070828
CA 2662434	A1	20080313	CA 2007-2662434	20070828
WO 2008030359	A2	20080313	WO 2007-US18892	20070828
WO 2008030359	A3	20080731		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2066313	A2	20090610	EP 2007-837413	20070828
------------	----	----------	----------------	----------

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.:			
	US 2006-824642P	P	20060906
	US 2007-893888P	P	20070309
	US 2007-842201	A	20070821
	WO 2007-US18892	W	20070828


AB Topical compns. are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a drug and a solvent system, wherein the solvent system comprises at least 2 solvent alcs. and wherein the solvent system is present in an amount sufficient to solubilize the drug, the solvent system is a low alkanol system, and the composition is a single phase composition Exemplary solvent systems are those

for which one of the at least two solvent alcs. is polyethylene glycol, glycerin, butylene glycol, dipropylene glycol, propylene glycol, ethanol, isopropanol, or a derivative thereof. Optionally the local inflammatory disorder is pseudofolliculitis barbae, dermatitis, psoriasis, wounds, or sunburn.


IT 60576-13-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical compns. containing NSAIDs and alcs. as solvents)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




L4 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1439962 CAPLUS
 DOCUMENT NUMBER: 150:89643
 TITLE: In Silico Functional Profiling of Small Molecules and Its Applications
 AUTHOR(S): Sato, Tomohiro; Matsuo, Yo; Honma, Teruki; Yokoyama, Shigeyuki
 CORPORATE SOURCE: Department of Biophysics and Biochemistry, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
 SOURCE: Journal of Medicinal Chemistry (2008), 51(24), 7705-7716
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB In silico screening is routinely used in the drug discovery process to predict whether each mol. in a database has a function of interest, such as inhibitory activity for a target protein. However, drugs generally have multiple functions including adverse effects. To obtain small mols. with desirable physiol. effects, it is useful to simultaneously predict as many functions as possible. The authors employed Support Vector Machine to build classification models for 125 mol. functions, derived from the MDDR database, which showed higher kappa statistics (0.775 on average) than those of predictions by Tanimoto similarity (0.708). By analyzing the patterns of the predicted values (functional profiles) of 871 marketed drugs, the authors demonstrated its applications to indication discovery, clustering of drugs, and detection of mol. actions related to adverse effects. The results showed that functional profiling can be a useful tool for identifying the multi-functionality or adverse effects of small mols.
 IT 60576-13-8
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
 (in silico functional profiling of small mols. and its applications)
 RN 60576-13-8 CAPLUS
 CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER: 2008:619334 CAPLUS
DOCUMENT NUMBER: 148:586136
TITLE: Synthetic peptide amides and dimers as kappa opioid
receptor agonists for treatment of pain and
inflammation
INVENTOR(S): Schteingart, Claudio D.; Menzaghi, Frederique; Jiang,
Guangcheng; Alexander, Roberta Vezza; Sueiras-Diaz,
Javier; Spencer, Robert H.; Chalmers, Derek T.; Luo,
Zhiyong
PATENT ASSIGNEE(S): Cara Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 158pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008060552	A2	20080522	WO 2007-US23874	20071113
WO 2008060552	A3	20081231		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA AU 2007319831 A1 20080522 AU 2007-319831 20071113 CA 2667460 A1 20080522 CA 2007-2667460 20071113 EP 2079756 A2 20090722 EP 2007-861995 20071113 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS KR 2009085097 A 20090806 KR 2009-711455 20071113 PRIORITY APPLN. INFO.: US 2006-858120P P 20061110 US 2006-858121P P 20061110 US 2006-858123P P 20061110 US 2007-928527P P 20070510 US 2007-928551P P 20070510 US 2007-928557P P 20070510 WO 2007-US23874 W 20071113				
OTHER SOURCE(S): MARPAT 148:586136				
GI				



II



III




AB The invention relates to synthetic peptide amide ligands of the kappa opioid receptor Xaa1Xaa2Xaa3(Xaa4)a-G [I; Xaa1-Xaa3 = substituted D-amino acids; Xaa4 = D-amino acids, cis- and trans- α ,4-diaminocyclohexaneacetic acid, cis- and trans- α -amino-4-guanidinocyclohexaneacetic acid, etc.; G = (Xaa1)^m(Xaa2)ⁿ(Xaa3)^p(Xaa4)^qL; m-p = independently 0-1; q, a = independently 0-1, provided that at least one of q and a = 1; L = linker selected from ϵ -D-Lys, δ -Lys, δ -D-Orn, δ -Orn, γ -aminobutyric acid, 8-aminooctanoic acid, 11-aminoundecanoic acid, 8-amino-3,6-dioxaoctanoic acid, 4-amino-4-piperidinecarboxylic acid, (D-LysGly lactam)₂; or G = II; J = 5-7 membered heterocyclyl containing 1-3 heteroatoms in the ring; R3, R4 = independently alkyl, halo, OH, CF₃, NH₂, CO₂H, amidino; R5, R6 = independently oxo, R3; W' = absent, provided that when W' = absent, Y = N; or W' = NH(CH₂)_b; b = 0-6 or W' = NH(CH₂)_cO; c = 2-3; their stereoisomers, mixture of stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, acid salt hydrates, N-oxides or isomorphous crystalline forms and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain for treatment of pain and inflammation associated with a variety of diseases and conditions. The invention also relates to synthetic peptide amide in which G = II; when G = II, a = 1, Xaa3-Xaa4 = D-Nle-(B)2D-Arg-, D-Leu- δ -(B)2 α -(B')D-Orn-, (α -Me)D-Leu- δ -(B)2- α -(B')D-Orn-, and Y, Z = independently C, or N which are not adjacent ring atoms, provided that when such ring moiety is 6-8 membered ring, Y and Z are separated by at least 2 ring atoms and provided that when such ring moiety has a single ring heteroatom which is N, then such ring moiety is nonarom.; W = one of W'; V = V'e; V' = alkyl and e = 0-1; when e = 0, V = absent and R1 and R2 are directly bonded to the same or different ring atoms; R1 = H, OH, halo, amidino, Pro-amide, alkyl, Lys, Arg, etc.; R2 = H, amidino, singly or doubly alkyl substituted amidino, CN, CONH₂ and derivs., etc.; R1 and R2 taken together can form an optionally substituted 4-9 membered monocyclol or bicyclol heterocyclyl which is bonded to a single ring atom of the Y and Z-containing ring moiety; or R1 and R2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4-8 membered heterocyclic ring moiety to form a spiro structure; or R1 and R2 taken together with two or more adjacent ring atoms of the Y and Z-containing ring

moiety can form an optionally substituted 4-9 membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety. Furthermore, when G = III, YZ = 4-8 membered heterocyclic ring, wherein Y = C or N and Z = C, N, O, S, SO, SO₂, provided that when such ring moiety is 6-8 membered ring, Y and Z are separated by at least 2 ring atoms and provided that when such ring is nonarom. and Z = C or N then such ring moiety contains at least one S or O heteroatom, and provided further that when such ring is aromatic, then Y = C. Eleven biol. examples are given. Thus, peptide amide IV was prepared on 2-chlorotrityl chloride resin using Boc-D-Phe-OH, Fmoc-D-Phe-OH, Fmoc-D-Leu-OH, Fmoc-D-Orn(Boc)-OH, and 2-carboxy-4-[[fluoren-9-yl)methoxy]carbonyl]morpholine. The potency of the peptide amides I as kappa opioid receptor agonists was determined by measuring the inhibition of forskolin-stimulated adenylate cyclase activity in mouse R1.G1 cells; EC₅₀ = 0.178 nM and efficacy = 100% for IV. I and their pharmaceutical compns. are useful for treating visceral pain, neuropathic pain, hyperalgesia and inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma.

IT 60576-13-8, Piketopropfen
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (synthetic peptide amide ligands of κ -opioid receptors useful in prophylaxis, treatment and combination therapy of pain and inflammation associated with variety of diseases)

RN 60576-13-8 CAPLUS
 CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



L4 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:585809 CAPLUS
 DOCUMENT NUMBER: 148:562184
 TITLE: Synthetic peptide amides as kappa opioid receptor agonists for treatment of pain and inflammation
 INVENTOR(S): Schteingart, Claudio D.; Menzaghi, Frederique; Jiang, Guangcheng; Alexander, Roberta Vezza; Sueiras-Diaz, Javier; Spencer, Robert H.; Chalmers, Derek T.; Luo, Zhiyong
 PATENT ASSIGNEE(S): Cara Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008057608	A2	20080515	WO 2007-US23858	20071112

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM



AU 2007317817	A1	20080515	AU 2007-317817	20077112
CA 2667155	A1	20080515	CA 2007-2667155	20077112
EP 2064228	A2	20090603	EP 2007-870877	20077112

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

KR 2009085096	A	20090806	KR 2009-711454	20077112
---------------	---	----------	----------------	----------

PRIORITY APPLN. INFO.:	US 2006-858109P	P	20067110
	US 2007-928550P	P	20070510
	WO 2007-US23858	W	20077112

OTHER SOURCE(S): MARPAT 148:562184
GI



II

AB The invention relates to synthetic peptide amide ligands of the kappa opioid receptor I [Xaa¹-Xaa³ = substituted D-amino acids; Xaa⁴ = D-amino acids, cis- and trans- α ,4-diaminocyclohexanecarboxylic acid, cis- and trans- α -amino-4-guanidinocyclohexanecarboxylic acid; W = absent, provided that when W = absent, Y = N; or W = NH(CH₂)_m; m = 0-6 or W = NH(CH₂)_pO; p = 2-3, provided that Y = C; YZ = 4-8 membered heterocyclic ring, wherein all ring heteroatoms are N; Y, Z = independently C, N, provided that when such ring moiety is 6-8 membered ring, Y and Z are separated by at least 2 ring atoms and provided that when such ring moiety has a single ring heteroatom which is N, then such ring moiety is nonarom.], their stereoisomers, mixture of stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, acid salt hydrates, N-oxides or isomorphous crystalline forms and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain for treatment of pain and inflammation associated with a

variety of diseases and conditions. Sixteen biol. examples are given. Thus, peptide amide II was prepared on p-nitrophenylcarbonate Wang resin using Cbz-D-Phe-OH, Fmoc-D-Phe-OH, Fmoc-D-Leu-OH, Fmoc-Lys(Dde)-OH [Dde = 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl] and homopiperazine. The potency of the peptide amides I as kappa opioid receptor agonists was determined by measuring the inhibition of forskolin-stimulated adenylate cyclase activity; EC50 = 0.043 nM and efficacy = 103% for II. I and their pharmaceutical compns. are useful for treating visceral pain, neuropathic pain, hyperalgesia and inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma.


IT 60576-13-8, Piketopropfen

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synthetic peptide amide ligands of κ -opioid receptors useful in prophylaxis and treatment and combination therapy of pain and inflammation associated with variety of diseases)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



L4 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2008:319393 CAPLUS

DOCUMENT NUMBER: 148:315378

TITLE: Topical compositions containing NSAIDs and alcohols as solvents

INVENTOR(S): Spann-Wade, Monique; Fedde, Kenton N.

PATENT ASSIGNEE(S): ISW Group, Inc., USA

SOURCE: PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008030359	A2	20080313	WO 2007-US18892	20070828
WO 2008030359	A3	20080731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,				

	GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA	
US 20080317684	A1 20081225	US 2007-842201 20070821
AU 2007293460	A1 20080313	AU 2007-293460 20070828
CA 2662434	A1 20080313	CA 2007-2662434 20070828
EP 2066313	A2 20090610	EP 2007-837413 20070828
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS	
IN 2009MN00457	A 20090515	IN 2009-MN457 20090304
PRIORITY APPLN. INFO.:		US 2006-82462P P 20060906
		US 2007-893888P P 20070309
		US 2007-842201 A 20070821
		WO 2007-US18892 W 20070828
AB	Topical compns. are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcs. and wherein the solvent system is present in an amount sufficient to solubilize the Drug, the solvent system is a low alkanol system, and the composition is a single phase composition Exemplary solvent systems are those	
for	which one of the at least two solvent alcs. is polyethylene glycol, glycerin, butylene glycol, dipropylene glycol, propylene glycol, ethanol, isopropanol, or a derivative thereof. Optionally the local inflammatory disorder is pseudofolliculitis barbae, dermatitis, psoriasis, wounds, or sunburn.	
IT	60576-13-8, Picketopfen RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. containing nsais and alcs. as solvents)	
RN	60576-13-8 CAPLUS	
CN	Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)	



L4 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:378611 CAPLUS

DOCUMENT NUMBER: 146:408390

TITLE: Transdermal delivery of non-steroidal anti-inflammatory drugs

INVENTOR(S): Klose, Kathryn Traci-Jane; Bakalova, Margarita Vladislavova; Morgan, Timothy Matthias; Finnin, Berrie Charles; Reed, Barry Leonard

PATENT ASSIGNEE(S): Acrux DDS Pty Ltd., Australia

SOURCE: U.S. Pat. Appl. Publ., 11pp., Cont.-in-part of U.S. Ser. No. 759,303.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070077288	A1	20070405	US 2006-517575	20060908
US 7387789	B2	20080617		
WO 9729735	A1	19970821	WO 1997-AU91	19970219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 1674068	A1	20060628	EP 2005-22951	19970219
EP 1674068	B1	20081008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1769785	A1	20070404	EP 2006-25287	19970219
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 6299900	B1	20011009	US 1998-125436	19981218
AU 9952589	A	19991202	AU 1999-52589	19991001
US 20020028235	A1	20020307	US 2001-910780	20010724
US 6818226	B2	20041116		
US 20040146469	A1	20040729	US 2004-759303	20040120
US 7438203	B2	20081021		
JP 2007326867	A	20071220	JP 2007-185782	20070717
PRIORITY APPLN. INFO.:				
			AU 1996-8144	A 19960219
			WO 1997-AU91	W 19970219
			US 1998-125436	A3 19981218
			US 2001-910780	A2 20010724
			US 2004-759303	A2 20040120
			AU 1997-17134	A3 19970219
			EP 1997-904304	A3 19970219
			EP 2005-22951	A3 19970219
			JP 1997-528834	A3 19970219
OTHER SOURCE(S): MARPAT 146:408390				
AB	The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a non-steroidal anti-inflammatory drug; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid Enhanced skin penetration of ibuprofen using Padimate O in a transdermal gel composition shows the cumulative amount of ibuprofen penetration into a microdialysis probe, adjusted for individual probe recovery over 24 h.			
IT	60576-13-8, Picketopfen RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (transdermal delivery of NSAIDs)			
RN	60576-13-8 CAPLUS			
CN	Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)			



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)


L4 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:945510 CAPLUS
 DOCUMENT NUMBER: 145:342419
 TITLE: Topical gel NSAIDs compositions
 INVENTOR(S): Spann-Wade, Monique; Ward, Anthony J.
 PATENT ASSIGNEE(S): Isw Group, Inc., USA
 SOURCE: PCT Int. Appl., 88pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006096360	A1	20060914	WO 2006-US6780	20060227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070053984	A1	20070308	US 2006-361384	20060224
AU 2006220964	A1	20060914	AU 2006-220964	20060227
CA 2599968	A1	20060914	CA 2006-2599968	20060227
EP 1858503	A1	20071128	EP 2006-736159	20060227
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008531693	T	20080814	JP 2007-558091	20060227
IN 2007MN01300	A	20071109	IN 2007-MN1300	20070827
ZA 2007007375	A	20081126	ZA 2007-7375	20070830
MX 2007010681	A	20071207	MX 2007-10681	20070831
CN 101151028	A	20080326	CN 2006-80010056	20070927
KR 2008008321	A	20080123	KR 2007-722557	20071002
PRIORITY APPLN. INFO.:			US 2005-658084P	P 20050303
			US 2005-681102P	P 20050513
			US 2005-690201P	P 20050614
			US 2006-361384	A 20060224
			WO 2006-US6780	W 20060227

AB Topical alc. gel compns. are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compns. comprise a topically active drug, an alc. solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alc. and alc.-free topical compns. comprising an NSAID prodrug are also disclosed. The compns. are particularly useful for the treatment of pseudo folliculitis barbae. A composition contained Carbomer Ultrez 10, ethanol, and ibuprofen. In some alc. formulations esters or ethers of NSAIDs were formed as prodrugs.

IT 60576-13-8, Picketoprofen
 RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(topical gel NSAIDs compns.)
 RN 60576-13-8 CAPLUS
 CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA
 INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:675225 CAPLUS

DOCUMENT NUMBER: 145:499756

TITLE: Greater allergenicity of topical ketoprofen in contact
 dermatitis confirmed by use

AUTHOR(S): Diaz, Ruth L.; Gardeazabal, Jesus; Manrique, Pilar;
 Raton, Juan A.; Urrutia, Ignacio; Rodriguez-Sasiain,
 Jose M.; Aguirre, Carmelo

CORPORATE SOURCE: Pharmacovigilance Unit, Galdakao, Spain
 SOURCE: Contact Dermatitis (2006), 54(5), 239-243

CODEN: CODEDG; ISSN: 0105-1873

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The use of topical non-steroidal anti-inflammatory drugs (NSAIDs) is very
 popular in spite of their doubtful efficacy and high number of generally not
 serious, but preventable, adverse effects, especially photoallergy. The
 allergenic potential of different topical NSAIDs was determined by performing a
 retrospective observational study of the period 1996-2001 and comparing
 the cases of allergy and photoallergy with the use of each topical NSAID.
 The diagnoses were obtained from a review of the clin. records of
 patch/photopatch testing carried out in the dermatol. departments of 2
 public hospitals in Bizkaia (Spain). The use of the different topical
 NSAIDs was obtained from invoices sent to the National Health System and
 the Reporting odds ratio (ROR) and Proportional reporting ratio (PRR)
 disproportionality ests. of the FEDRA database of the Spanish
 Pharmacovigilance System. A total of 139 contact reactions to topical
 NSAIDs were found with ketoprofen being responsible for 28% of the
 allergies and 82% of the contact photoallergies in spite of not being the
 most used topical NSAID (third in the ranking, diclofenac was the first).
 The ROR for ketoprofen was 3.9 (2.4-6.4) and the PRR 3.4 (2.1-5.5), thus
 confirming the possibility of a warning signal. The results support the
 need for regulatory action on topical ketoprofen.

IT 60576-13-8, Piketopropfen

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (non-steroidal anti-inflammatory drug, piketopropfen caused allergy in
 patient with contact dermatitis)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA
 INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:902714 CAPLUS
DOCUMENT NUMBER: 143:235463
TITLE: Combination of proton pump inhibitor, buffering agent,
and nonsteroidal anti-inflammatory agent
INVENTOR(S): Proehl, Gerald T.; Olmstead, Kay; Hall, Warren
PATENT ASSIGNEE(S): Santarus, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076987	A2	20050825	WO 2005-US3791	20050204
WO 2005076987	A3	20060608		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005213472	A1	20050825	AU 2005-213472	20050204
CA 2554271	A1	20050825	CA 2005-2554271	20050204
US 20050249806	A1	20051110	US 2005-51260	20050204
EP 1718303	A2	20061108	EP 2005-722791	20050204
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
JP 2007522217	T	20070809	JP 2006-553174	20050204
MX 2006009036	A	20061019	MX 2006-9036	20060809
PRIORITY APPLN. INFO.:			US 2004-543636P	P 20040210
			WO 2005-US3791	W 20050204

AB Pharmaceutical compns. comprising a proton pump inhibitor, one or more buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid-related disorders and treating inflammatory disorders, using pharmaceutical compns. comprising a proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug. For example, a powder for suspension formulation contained omeprazole 20 mg, ibuprofen 400 mg, sodium bicarbonate 1895 mg,


Xylitol 300 (sweetener) 2000 mg, sucrose (sweetener) 1750 mg, sucralose (sweetener) 125 mg, xanthan gum 17 mg, peach flavor 47 mg, and peppermint 26 mg.

IT 60576-13-8, Piketoprofen

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of proton pump inhibitor, buffering agent, and NSAID agent
for treatment of gastric acid-related disorders and
inflammation)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA
INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(10 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:490281 CAPLUS

DOCUMENT NUMBER: 143:48056

TITLE: Novel nanoparticulate nimesulide compositions

INVENTOR(S): Bosch, H. William; Wertz, Christian F.

PATENT ASSIGNEE(S): Elan Pharma International Ltd., Ire.

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051356	A1	20050609	WO 2003-US32731	20031031
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2544404	A1	20050609	CA 2003-2544404	20031031
AU 2003303744	A1	20050617	AU 2003-303744	20031031
EP 1684725	A1	20060802	EP 2003-815810	20031031
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK			
JP 2007522079	T	20070809	JP 2005-510942	20031031
PRIORITY APPLN. INFO.:			WO 2003-US32731	W 20031031


AB The present invention provides nanoparticulate nimesulide compns. The

comps. preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide comps. An aqueous solution of 1% (weight/weight) Plasdone S-630 was combined with 4.25 g of nimesulide (5% weight/weight) and stirred for 1 h at 4200 rpm with chilled water (10°) recirculated through the milling chamber. The process yielded a colloidal dispersion of nimesulide with a mean particle size of 150 nm, a D50 of 124 nm, a D90 of 256 nm, and a D95 of 293 nm.

IT 60576-13-8, Piketopropfen
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel nanoparticulate nimesulide comps.)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:449442 CAPLUS

DOCUMENT NUMBER: 142:469343

TITLE: Use of piketopropfen for manufacture of a pharmaceutical composition for the treatment of rosacea

INVENTOR(S): Folfi, Fabrizio; Pilgrim, William Robert

PATENT ASSIGNEE(S): Galderma Research & Development, Fr.

SOURCE: Fr. Demande, 15 pp.
 CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2862539	A1	20050527	FR 2003-13665	20031121
FR 2862539	B1	20060303		
CA 2545085	A1	20050707	CA 2004-2545085	20041110
WO 2005060962	A1	20050707	WO 2004-FR2898	20041110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,


AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1686991 A1 20060809 EP 2004-805439 20041110
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
 US 20070149620 A1 20070628 US 2006-580254 20061214
 PRIORITY APPLN. INFO.: FR 2003-13665 A 20031121
 WO 2004-FR2898 W 20041110

AB The present invention refers to the use of piketoprogen for the preparation of new pharmaceutical compns. useful for the treatment of rosacea. The prepn. contain 0.0001-20% and particularly 0.001-10% piketoprogen (no data).

IT 60576-13-8, Piketoprogen
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of piketoprogen for manufacture of pharmaceutical composition for treatment of rosacea)

RN 60576-13-8 CAPLUS
 CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:17015 CAPLUS
 DOCUMENT NUMBER: 142:120515
 TITLE: Dispersible formulations containing anti-inflammatory agents and other active ingredients for infusion
 INVENTOR(S): Britten, Nancy Jean; Waldron, Niki Ann; Watts, Jeffrey L.; Hallberg, John Walter; Burns, John W.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 803,146.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050004098	A1	20050106	US 2004-909050	20040730
US 20040235803	A1	20041125	US 2004-803146	20040317
AU 2004258745	A1	20050203	AU 2004-258745	20040719
CA 2533101	A1	20050203	CA 2004-2533101	20040719
WO 2005009436	A1	20050203	WO 2004-IB2461	20040719

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1651210 A1 20060503 EP 2004-744112 20040719
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1829510	A	20060906	CN 2004-80022099	20040719
BR 2004012581	A	20060919	BR 2004-12581	20040719
JP 2007500691	T	20070118	JP 2006-521702	20040719
RU 2319508	C2	20080320	RU 2006-101628	20040719
IN 2005DN06136	A	20070824	IN 2005-DN6136	20051229
ZA 2006000096	A	20070228	ZA 2006-96	20060103
KR 2006031873	A	20060413	KR 2006-702034	20060127
KR 780983	B1	20071130		
MX 2006001288	A	20060411	MX 2006-1288	20060131
NO 2006000982	A	20060502	NO 2006-982	20060228

PRIORITY APPLN. INFO.:

US 2003-456325P	P	20030320
US 2003-492121P	P	20030731
US 2004-803146	A2	20040317
WO 2004-IB2461	W	20040719

OTHER SOURCE(S): MARPAT 142:120515


AB A method is provided for treatment and/or prevention of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical composition suitable for infusion into the organ according to the method of the invention, and a process for preparing such a composition. For example, a suspension to be administered by intramammary infusion was prepared containing parecoxib 100

mg/mL, Labrafil M-1944CS 50 mg/mL, microcryst. wax 70 mg/mL, and cottonseed oil q.s.

IT 60576-13-8, Piketopropfen
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dispersible formulation containing anti-inflammatory agents and other active ingredients for infusion)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:802681 CAPLUS

DOCUMENT NUMBER: 141:301462
 TITLE: Dispersible formulations of an anti-inflammatory agent
 INVENTOR(S): Britten, Nancy J.; Burns, John W.; Hallberg, John W.;
 Waldron, Niki A.; Watts, Jeffrey L.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082588	A2	20040930	WO 2004-IB826	20040310
WO 2004082588	A3	20041223		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004222523	A1	20040930	AU 2004-222523	20040310
CA 2519125	A1	20040930	CA 2004-2519125	20040310
EP 1608407	A2	20051228	EP 2004-719030	20040310
EP 1608407	B1	20060830		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
BR 2004008556	A	20060321	BR 2004-8556	20040310
CN 1761487	A	20060419	CN 2004-80007593	20040310
JP 2006520779	T	20060914	JP 2006-506364	20040310
AT 337793	T	20060915	AT 2004-719030	20040310
ES 2270361	T3	20070401	ES 2004-719030	20040310
RU 2325189	C2	20080527	RU 2005-129266	20040310
TW 262084	B	20060921	TW 2004-93107507	20040319
IN 2005DN03644	A	20070824	IN 2005-DN3644	20050818
ZA 2005006920	A	20070926	ZA 2005-6920	20050829
NO 2005004260	A	20051212	NO 2005-4260	20050915
PRIORITY APPLN. INFO.:			US 2003-456325P	P 20030320
			WO 2004-IB826	A 20040310
AB	A method is provided for treatment of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering, to the organ via the exterior orifice, a pharmaceutical composition comprising an anti-inflammatory agent and a vehicle that comprises an amphipathic oil that is water dispersible and ethanol insol., microcryst. wax and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the anti-inflammatory agent. The composition is readily dispersible in the fluid of the fluid-containing organ. Thus, a suspension to be administered by intramammary infusion comprised parecoxib 100, Labrafil M-1944CS 50, and microcryst. wax 70 mg/mL, and cottonseed oil qs.			
IT	60576-13-8, Piketopofen RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (dispersible formulations of anti-inflammatory agent)			
RN	60576-13-8 CAPLUS			
CN	Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)			



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:714114 CAPLUS

DOCUMENT NUMBER: 141:282985

TITLE: Evaluation of the pH effect of formulations on the skin permeability of drugs by biopartitioning micellar chromatography

AUTHOR(S): Martinez-Pla, J. J.; Martin-Biosca, Y.; Sagrado, S.; Villanueva-Camanas, R. M.; Medina-Hernandez, M. J.

CORPORATE SOURCE: Facultat de Farmacia, Departamento de Quimica Analitica, Universitat de Valencia, Burjassot, Valencia, E-46100, Spain

SOURCE: Journal of Chromatography, A (2004), 1047(2), 255-262 CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Dermal absorption of chems. is an area of increasing interest for the pharmaceutical and cosmetic industries, as well as in dermal exposure and risk assessment processes. Biopartitioning micellar chromatog. (BMC) is a mode of reversed phase micellar chromatog. that has proved to be useful in the description and prediction of several pharmacol. properties of xenobiotics including oral drug absorption, ocular and skin drug permeability. The present paper deals with the application of biopartitioning micellar chromatog. to evaluate the pH effect on the skin permeability of twelve non-steroidal anti-inflammatory drugs and lidocaine. For this purpose the BMC retention of the whole set of compds. at several pHs between 3.5 and 8 was obtained. Using the BMC retention-permeability model previously reported, the permeability of the compds. at different pH values was estimated. The predicted permeability values at different pH values for ketoprofen, lidocaine, salicylic acid and ibuprofen agree with those exptl. reported in literature for these compds. using excised human and rat skin.

IT 60576-13-8, Piktetopfen

RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(pH effect of formulations on skin permeability of drugs by biopartitioning micellar chromatog.)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS
RECORD (15 CITINGS)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:633448 CAPLUS
DOCUMENT NUMBER: 139:185666
TITLE: Coated pharmaceutical tablets with speckled appearance
INVENTOR(S): Martino, Alice C.; Noack, Robert M.; Pierman, Steven
A.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066030	A2	20030814	WO 2003-US3837	20030206
WO 2003066030	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2474921	A1	20030814	CA 2003-2474921	20030206
AU 2003210930	A1	20030902	AU 2003-210930	20030206
AU 2003210930	B2	20070104		
US 20030180357	A1	20030925	US 2003-359939	20030206
EP 1480624	A2	20041201	EP 2003-737712	20030206
EP 1480624	B1	20061129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007593	A	20050201	BR 2003-7593	20030206
JP 2005517693	T	20050616	JP 2003-565454	20030206
JP 4174426	B2	20081029		
CN 1630512	A	20050622	CN 2003-803580	20030206
CN 1267087	C	20060802		
NZ 533957	A	20060224	NZ 2003-533957	20030206
RU 2273473	C2	20060410	RU 2004-124065	20030206
AT 346591	T	20061215	AT 2003-737712	20030206
ES 2274248	T3	20070516	ES 2003-737712	20030206
MX 2004006799	A	20041206	MX 2004-6799	20040713

ZA 2004005556	A	20050810	ZA 2004-5556	20040713
IN 2004DN02122	A	20071019	IN 2004-DN2122	20040722
NO 2004003716	A	20040906	NO 2004-3716	20040906
HK 1074581	A1	20061020	HK 2005-106918	20050811
PRIORITY APPLN. INFO.:			US 2002-355705P	P 20020207
			WO 2003-US3837	W 20030206


OTHER SOURCE(S): MARPAT 139:185666

AB A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

IT 60576-13-8, Piketopufen
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (active ingredients for coated pharmaceutical tablets with speckled appearance)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:633447 CAPLUS

DOCUMENT NUMBER: 139:185665

TITLE: Pharmaceutical dosage form for mucosal delivery

INVENTOR(S): Martino, Alice C.; Piermar, Steven A.; Noack, Robert M.; Britten, Nancy

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066029	A2	20030814	WO 2003-US3836	20030206
WO 2003066029	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2474190 A1 20030814 CA 2003-2474190 20030206
AU 2003215110 A1 20030902 AU 2003-215110 20030206
AU 2003215110 B2 20071129
US 20030235617 A1 20031225 US 2003-360167 20030206
EP 1471890 A2 20041103 EP 2003-710927 20030206
EP 1471890 B1 20060927

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003007473 A 20041109 BR 2003-7473 20030206
CN 1627938 A 20050615 CN 2003-803419 20030206
CN 100346832 C 20071107
JP 2005519924 T 20050707 JP 2003-565453 20030206
NZ 534340 A 20060428 NZ 2003-534340 20030206
AT 340565 T 20061015 AT 2003-710927 20030206
RU 2285520 C2 20061020 RU 2004-124057 20030206
ES 2271542 T3 20070416 ES 2003-710927 20030206
ZA 2004005614 A 20050627 ZA 2004-5614 20040714
IN 2004DN02055 A 20090313 IN 2004-DN2055 20040716
MX 2004007728 A 20041110 MX 2004-7728 20040809
NO 2004003723 A 20040906 NO 2004-3723 20040906
PRIORITY APPLN. INFO.: US 2002-355703P P 20020207
WO 2003-US3836 W 20030206


OTHER SOURCE(S): MARPAT 139:185665

AB A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.

IT 60576-13-8, Piketoprofen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active ingredients for coated sublingual tablets)

RN 60576-13-8 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN


ACCESSION NUMBER: 1986:412009 CAPLUS

DOCUMENT NUMBER: 105:12009


ORIGINAL REFERENCE NO.: 105:2005a,2008a

TITLE: Percutaneous absorption of piketoprofen in rabbits: effect of nonionic surface-active agents

AUTHOR(S): Fabregas, J. L.; Cucala, J.; Segura, J.; Tarrus, E.
 CORPORATE SOURCE: Inst. Res., Lab. Almirall, S. A., Barcelona, Spain
 SOURCE: Farmaco, Edizione Pratica (1986), 41(5), 177-83
 CODEN: FRPPAO; ISSN: 0430-0912
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Skin absorption in rabbits of piketoprofen (I) [60576-13-8] from topical creams was optimum from a formulation contg I 1.8, Tween 20 [9005-64-5] 3, Span 20 [1338-39-2] 2, Eumulgin B-2 2, long chain alcs. 24.9 and H2O 66.3%. Addition of Tween 20 enhanced skin absorption the most of the 3 surfactants. The presence of the surfactants at a concentration slightly above the critical micelle concentration ensures a high concentration of I in the organic phase without the risk of hydrolysis.
 IT 60576-13-8
 RL: BIOL (Biological study)
 (skin absorption of, from creams, nonionic surfactants effect on)
 RN 60576-13-8 CAPLUS
 CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L4 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1985:190986 CAPLUS
 DOCUMENT NUMBER: 102:190986
 ORIGINAL REFERENCE NO.: 102:29889a,29892a
 TITLE: Optimization of the dermal absorption of a new antiinflammatory (piketoprofen)
 AUTHOR(S): Tarrus, E.; Puget, G.; Fabregas, J. L.; Celdran, E.; Segura, J.
 CORPORATE SOURCE: Inst. Invest., Lab. Almirall, Barcelona, Spain
 SOURCE: Biopharm. Pharmacokinet., Eur. Congr., 2nd (1984), Volume 1, 483-91. Editor(s): Aiache, J. M.; Hirtz, J. Lavoisier: Paris, Fr.
 CODEN: 53JFAA
 DOCUMENT TYPE: Conference

LANGUAGE: Spanish
GI



AB Piketopufen (I) [60576-13-8] cream and aerosol formulations
(200 mg/kg) which gave optimum percutaneous absorption by rabbit
skin were reported. Highly satisfactory clin. results were
obtained as compared to other topical antiinflammatories.
IT 60576-13-8
RL: BIOL (Biological study)
(aerosols and creams, skin absorption of, in humans and laboratory
animals)
RN 60576-13-8 CAPLUS
CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA
INDEX NAME)



L4 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1981:174892 CAPLUS
DOCUMENT NUMBER: 94:174892
ORIGINAL REFERENCE NO.: 94:28571a,28574a
TITLE: 2-Amino-4-methylpyridine amide
PATENT ASSIGNEE(S): Fordonal S. A., Spain
SOURCE: Belg., 7 pp.
CODEN: BEXXAL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
BE 882711	A1	19800731	BE 1980-200169	19800409
ES 488909	A1	19810216	ES 1980-488909	19800225
PRIORITY APPLN. INFO.: GI			ES 1980-488909	A 19800225




AB The analgesic and antiinflammatory (no data) amide I was obtained in 85.2% yield by treating 2-amino-4-methylpyridine with PC13 and treating the resulting phosphoramidimide with 3-BzC6H4CHMeCO2H.

IT 59512-37-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59512-37-7 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L4 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1977:43691 CAPLUS

DOCUMENT NUMBER: 86:43691

ORIGINAL REFERENCE NO.: 86:6957a,6960a

TITLE: Amide derivatives of 3-benzoyl-phenylalkanoic acids

INVENTOR(S): Spickett, Robert G. W.; Vega Noverola, Armando; Prieto Soto, Jose

PATENT ASSIGNEE(S): Gallardo, Antonio, S. A., Spain

SOURCE: Brit., 5 pp.
CODEN: BRXXAA

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1436502	A	19760519	GB 1974-43098	19741004
PRIORITY APPLN. INFO.:			ES 1973-419319	A 19731004


AB Twelve title amides 3-PhCOC6H4CHRCO2NR1R2 (I; R = H, Me; R1 = H; R2 = 4-methyl-2-pyridyl, 2-thiazolinyl, 2-thiazolyl, 3-hydroxy-2-pyridyl, 3-pyridyl, 1,5-dimethyl-2-phenyl-4-pyrazolinyl, 3-oxo-4,5-benzo-1,2-thiazolin-2-yl 1,1-dioxide), useful as inflammation inhibitors, analgesics, and antipyretics, were prepared from 3-PhCOC6H4CHRCOCl by heating with R1NHR2 and Et3N in dioxane 2 hr at 80°. The antiinflammatory, analgesic, and antipyretic activities of I were assessed; the activities of I (R = R1 = H, R2 =

4-methyl-2-pyridyl, 2-thiazoliny; R = Me, R1 = H, R2 =
 4-methyl-2-pyridyl) were intermediate between those of phenylbutazone and
 indomethacin. Compns. containing I are described.
 IT 59512-37-7P 60576-13-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (inflammation inhibitor, analgesic, and antipyretic, preparation
 of)
 RN 59512-37-7 CAPLUS
 CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)-,
 hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 60576-13-8 CAPLUS
 CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)- (CA
 INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

L4 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1976:428629 CAPLUS
 DOCUMENT NUMBER: 85:28629
 ORIGINAL REFERENCE NO.: 85:4613a, 4616a
 TITLE: Anti-inflammatory and related pharmacological
 properties of amides of substituted aryl alkanolic
 acids
 AUTHOR(S): Spickett, Robert G. W.; Vega, Armando; Prieto, Jose;
 Moragues, Jacinto; Marquez, Miguel; Roberts, David J.
 CORPORATE SOURCE: Inst. Invest., Lab. Almirall S. A., Barcelona, Spain
 SOURCE: European Journal of Medicinal Chemistry (1976), 11(1),
 7-12
 CODEN: EJMCA5; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Of the 29 amides of ibuprofen and ketoprofen and the acetic acid derivative of ketoprofen (I) studied, the heterocyclic amides of ketoprofen possessed a high degree of antiinflammatory activity. The most interesting of these compounds, 2-[2-(m-benzoylphenyl)-propionamido]-4-methyl pyridine-HCl [59512-37-7], was studied in more detail. The amides were prepared from the appropriate acid chlorides.

IT 59512-37-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antiinflammatory activity of)

RN 59512-37-7 CAPLUS

CN Benzeneacetamide, 3-benzoyl- α -methyl-N-(4-methyl-2-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

=> s nsaid and rosacea
 7054 NSAID
 1038 ROSACEA

L5 6 NSAID AND ROSACEA

=> d l5 1-5 ibib abs hitstr

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:146007 CAPLUS

DOCUMENT NUMBER: 150:183438

TITLE: Multifunctional and combinational application of aspartame and/or futhan

INVENTOR(S): Hugli, Tony E.; Adams, John E.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 31pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017742	A1	20090205	WO 2008-US9184	20080730
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090036528	A1	20090205	US 2008-220949	20080730
PRIORITY APPLN. INFO.: US 2007-962651P P 20070731 US 2007-964987P P 20070816				
AB The invention is an application, composition, and method for using a pharmaceutically effective amount of aspartame or its primary metabolite aspartylphenylalanine in systematic and periodic application or dose as an aspirin (NSAID) substitute, treatment for osteoporosis, and or topical treatment for rosacea.				
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:502592 CAPLUS
 DOCUMENT NUMBER: 148:487220
 TITLE: Methods of using 4-phenylaminoquinoline compounds as topical non-steroidal antiinflammatory drugs
 INVENTOR(S): Wasley, Jan; Plattner, Jacob
 PATENT ASSIGNEE(S): Milestone Pharmaceuticals Inc., Can.
 SOURCE: PCT Int. Appl., 47pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008048577	A1	20080424	WO 2007-US22040	20071016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080139611	A1	20080612	US 2007-873116	20071016
PRIORITY APPLN. INFO.: US 2006-852191P P 20061017				
OTHER SOURCE(S): MARPAT 148:487220				
GI				



AB The invention discloses the preparation and use of 4-phenylaminoquinolines I (X= H, F, Br, CF₃; Y= N, N-oxide; R= H, lower alkyl, lower alkoxyalkyl, lower hydroxyalkyl; or pharmaceutically acceptable salts thereof) for topical treatment of skin disorders, disorders associated with pain, fever, or inflammation, and proliferative and ocular disorders.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:80343 CAPLUS

DOCUMENT NUMBER: 140:122836

TITLE: Use of 2,3-alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals

INVENTOR(S): Stec, Karen; Rubinstein, Israel; Eiznhamer, David; Xu, Ze-qu; Flavin, Michael

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040019022	A1	20040129	US 2003-622302	20030718
WO 2004010989	A1	20040205	WO 2003-US23644	20030718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003252178	A1	20040216	AU 2003-252178	20030718
EP 1539132	A1	20050615	EP 2003-772019	20030718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-398523P	P 20020725
			WO 2003-US23644	W 20030718

AB A method for the treatment of cellular and tissue damage is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof for the prevention and treatment of dysfunction, damage, and/or injuries to organs, tissues and/or cells in human or animal subjects caused by diseases, infections and conditions such as pneumonia, coronavirus, multiple transfusions, trauma, ischemic-reperfusion

dysfunctions, stroke, drug overdose, and severe acute respiratory syndrome. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics. The acid may be administered in any practical delivery form, and in free acid or buffered form.

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:736096 CAPLUS
DOCUMENT NUMBER: 137:253017
TITLE: Dermatological formulations containing NSAIDS
INVENTOR(S): Arkin, Moshe; Zighelboim, Marcel; Lavon, Ilana; Zeevi, Amira
PATENT ASSIGNEE(S): Agis Industries (1983) Ltd., Israel
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074290	A2	20020926	WO 2002-IL179	20020307
WO 2002074290	A3	20040219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2440687	A1	20020926	CA 2002-2440687	20020307
AU 2002237489	A1	20021003	AU 2002-237489	20020307
EP 1414429	A2	20040506	EP 2002-703822	20020307
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20030039704	A1	20030227	US 2002-97434	20020315
PRIORITY APPLN. INFO.:			IL 2001-142037	A 20010315
			WO 2002-IL179	W 20020307
AB	The invention provides a method of treating or preventing Rosacea, comprising topical administration, of a pharmaceutical comprising a nonsteroidal anti-inflammatory drug. Thus, a gel formulation contained piroxicam 0.5, 95% EtOH 18, triethanolamine 0.6, Transcutol 17, methylparaben 0.027, propylparaben 0.014, Brij-35 0.6, Arlacel-186 0.016, Cetiol HE 6, hydroxyethyl cellulose 1.4, and water qs to 100%.			
OS.CITING REF COUNT:	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)		
REFERENCE COUNT:	18	THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:122747 CAPLUS
DOCUMENT NUMBER: 136:172774
TITLE: Topical delivery systems based on crosslinked poly(acrylic acid) for skin treatment
INVENTOR(S): Dow, Gordon J.; Lathrop, Robert W.; Dow, Debra A.
PATENT ASSIGNEE(S): Dow Pharmaceutical Sciences, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011683	A1	20020214	WO 2001-US23341	20010724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6387383	B1	20020514	US 2000-632508	20000803
CA 2417646	A1	20020214	CA 2001-2417646	20010724
AU 2001079002	A	20020218	AU 2001-79002	20010724
EP 1304992	A1	20030502	EP 2001-957238	20010724
EP 1304992	B1	20090429		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013247	A	20030624	BR 2001-13247	20010724
CN 1460013	A	20031203	CN 2001-815065	20010724
ZA 2003001037	A	20040209	ZA 2003-1037	20010724
JP 2004505900	T	20040226	JP 2002-517021	20010724
RU 2251410	C2	20050510	RU 2003-105831	20010724
AU 2001279002	B2	20060427	AU 2001-279002	20010724
CN 101305982	A	20081119	CN 2008-10085216	20010724
EP 2052714	A1	20090429	EP 2008-20820	20010724
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, LT, LV, SI				
AT 429922	T	20090515	AT 2001-957238	20010724
US 20020176891	A1	20021128	US 2002-96516	20020308
US 6517847	B2	20030211		
MX 2003001006	A	20050225	MX 2003-1006	20030131
KR 840169	B1	20080623	KR 2003-701564	20030203
IN 2003DN00126	A	20090327	IN 2003-DN126	20030203
KR 2008036246	A	20080425	KR 2008-708303	20080404
PRIORITY APPLN. INFO.:			US 2000-632508	A 20000803
			CN 2001-815065	A3 20010724
			EP 2001-957238	A3 20010724
			WO 2001-US23341	W 20010724
			KR 2003-701564	A3 20030203

AB A topical composition is provided for treating a skin disorder in a human subject that has a viscosity of less than about 15,000 cP and a pH of about 3.0 to 9.0. The composition consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a pharmaceutically-acceptable, lightly cross-linked poly(acrylic acid) polymer compatible with the therapeutic compound, (c) optionally a water miscible solvent, (d) optionally a preservative, (e) optionally an oil phase component and suitable surfactant, and (f) water. The therapeutic compound is an antibiotic, imidazole, retinoid, corticosteroid or a nonsteroidal anti-inflammatory drug. The composition is useful for treating an inflammatory skin disorder, acne, or rosacea. The low viscosity composition has an advantage of being administered more accurately when combined with a container that administers the composition as drops. For example, a pourable gel composition was prepared containing (by weight) clindamycin phosphate 1.19%, Me paraben 0.15%,

Carbopol 941 (or 981) 0.20%, propylene glycol 15.0%, polyethylene glycol
400 5.0%, NaOH (10% solution) as needed for pH 5.3-5.7, and water up to 100%.
OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
RECORD (11 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:32:56 ON 17 SEP 2009)

FILE 'REGISTRY' ENTERED AT 14:33:53 ON 17 SEP 2009

L1 2 S PIKETOPROFEN

FILE 'CAPLUS' ENTERED AT 14:34:30 ON 17 SEP 2009

L2 37 S L1

L3 11 S L2 AND SKIN

L4 21 S L2 AND (SKIN OR INFLAMMATION OR DERMATITIS)

L5 6 S NSAID AND ROSACEA

=>